The EMBO Journal
 
Advanced search
Journal home
Aims and scope
Current issue
Advance Online Publication
Web Focuses
Archive:-
Browse by issue
Browse by subject
Browse by category
Free online sample issue
Press releases
Authors & Referees
Editorial process
Guide for authors
Submit an article
Guide for referees
Editorial Team, Senior Advisors and Advisory Editorial Board
Contact Editorial office
Customer services
Subscribe
Order sample copy
Purchase articles
Reprints and permissions
Contact NPG
Advertising
EMBO
www.embo.org
Article
The EMBO Journal (1998) 17, 6608–6621, doi:10.1093/emboj/17.22.6608
Phosphorylation-dependent and constitutive activation of Rho proteins by wild-type and oncogenic Vav-2
Kornel E. Schuebel1, Nieves Movilla1, José Luis Rosa2 and Xosé R. Bustelo1
1 Department of Pathology, State University of New York at Stony Brook, University Hospital, Level 2, Room 718-B, Stony Brook, NY 11794-7025, USA
2 Present address: Unidad de Bioquímica (4178), Facultad de Medicina, Campus de Bellvitge, Universidad de Barcelona, C/ Feixa Llarga s/n, 08907 Hospitalet (Barcelona), Spain

To whom correspondence should be addressed
Xosé R. Bustelo, xbustelo@path.som.sunysb.edu

Received 25 March 1998; Revised 14 September 1998; Accepted 15 September 1998.
Abstract
We show here that Vav-2, a member of the Vav family of oncoproteins, acts as a guanosine nucleotide exchange factor (GEF) for RhoG and RhoA-like GTPases in a phosphotyrosine-dependent manner. Moreover, we show that Vav-2 oncogenic activation correlates with the acquisition of phosphorylation-independent exchange activity. In vivo, wild-type Vav-2 is activated oncogenically by tyrosine kinases, an effect enhanced further by co-expression of RhoA. Likewise, the Vav-2 oncoprotein synergizes with RhoA and RhoB proteins in cellular transformation. Transient transfection assays in NIH-3T3 cells show that phosphorylated wild-type Vav-2 and the Vav-2 oncoprotein induce cytoskeletal changes resembling those observed by the activation of the RhoG pathway. In contrast, the constitutive expression of the Vav-2 oncoprotein in rodent fibroblasts leads to major alterations in cell morphology and to highly enlarged cells in which karyokinesis and cytokinesis frequently are uncoupled. These results identify a regulated GEF for the RhoA subfamily, provide a biochemical explanation for vav family oncogenicity, and establish a new signaling model in which specific Vav-like proteins couple tyrosine kinase signals with the activation of distinct subsets of the Rho/Rac family of GTPases.
Keywords: GDP–GTP exchange factors, phosphorylation, Rac, Rho, Vav family
Send to a friendEmail link to a friend
PDFDownload PDF
Full textFull text
Next article
Previous article
Table of contents
rights and permissionsRights and permissions
order commercial reprintsReprints
ToC alertRegister for table of contents by email
  Privacy policy Copyright © 1998 by the European Molecular Biology Organization